01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsNextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell – Part of the Stem Cell Revolution

Stem and stromal cells are expected to revolutionize the treatment of today’s severe and incurable diseases. NextCell develops pioneering stromal cell therapies for the treatment of autoimmune and inflammatory diseases. NextCell's drug candidate, ProTrans, is at the forefront of our development for the treatment of type 1 diabetes.

NextCell's Product Portfolio

NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.
Read more

About NextCell

NextCell is a Swedish biopharmaceutical company operating in three business areas – Cellaviva, ProTrans and QVance – with the shared core being cell therapies and development of advanced therapy medicinal products (ATMPs).
Sample in a lab is being examinedRead more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Cover art of NextCell report
Read our latest report:
Annual report 2024/2025
Download

News

2026-05-06

NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

Regulatory
NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.
Read moreRead more
2026-05-04

NextCell Pharma publishes Annual Report 2024/2025

Regulatory
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Annual Report for the extended financial year September 1, 2024 – December 31, 2025. The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". 
Read moreRead more
2026-05-04

NextCell Pharma publishes Annual Report 2024/2025

Regulatory
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Annual Report for the extended financial year September 1, 2024 – December 31, 2025. The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". 
Read moreRead more
2026-03-13

ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy

Regulatory
NextCell Pharma AB (“NextCell” or the “Company”) announces that the Phase II clinical trial evaluating ProTrans® (allogeneic Wharton’s Jelly-derived mesenchymal stromal cells) for respiratory complications associated with COVID-19 has been accepted for publication in Cytotherapy (https://www.isct-cytotherapy.org/article/S1465-3249(26)00736-X/abstract), the official journal of the International Society for Cell & Gene Therapy.
Read moreRead more
All news

Subscribe to press releases

By filling out the form you are approving that NextCell Pharma stores your information. Read more about our integrity policy here.
I am not a robot.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please try again.
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept